Table 3.
Summary of Adverse Events
| Adverse Events System Organ Class Preferred Term (MedDRA 17.1) | Period | Total (N=12) | ||
|---|---|---|---|---|
| Evogliptin (N=12) | Rifampicin (N=11) | Evogliptin + Rifampicin (N=11) | ||
| Total | 1 (8.3) | 4 (36.4) | 1 (9.1) | 5 (41.7) |
| Gastrointestinal disorders | – | 1 (9.1) | – | 1 (8.3) |
| Lip dry | – | 1 (9.1) | – | 1 (8.3) |
| Respiratory, thoracic, and mediastinal disorders | – | 2 (18.2) | – | 2 (16.7) |
| Pharyngitis | – | 1 (9.1) | – | 1 (8.3) |
| Rhinorrhea | – | 1 (9.1) | – | 1 (8.3) |
| General disorders and administration site conditions | – | – | 1 (9.1) | 1 (8.3) |
| Administration site paresthesia | – | – | 1 (9.1) | 1 (8.3) |
| Musculoskeletal and connective tissue disorders | – | 1 (9.1) | – | 1 (8.3) |
| Myalgia intercostal | – | 1 (9.1) | – | 1 (8.3) |
| Nervous system disorders | 1 (8.3) | – | – | 1 (8.3) |
| Headache | 1 (8.3) | – | – | 1 (8.3) |
| Skin and subcutaneous tissue disorders | – | 1 (9.1) | – | 1 (8.3) |
| Hyperhidrosis | – | 1 (9.1) | – | 1 (8.3) |
Note: Unit: number of subjects (%).